Open Access

Is age a risk factor for liver disease and metabolic alterations in ataxia Telangiectasia patients?

  • Talita Lemos Paulino1,
  • Marina Neto Rafael1,
  • Sonia Hix2,
  • David Carlos Shigueoka3,
  • Sergio Aron Ajzen3,
  • Cristiane Kochi4,
  • Fabíola Isabel Suano-Souza1Email author,
  • Rosangela da Silva5,
  • Beatriz T. Costa-Carvalho1 and
  • Roseli O. S. Sarni1
Contributed equally
Orphanet Journal of Rare Diseases201712:136

https://doi.org/10.1186/s13023-017-0689-y

Received: 15 December 2016

Accepted: 31 July 2017

Published: 4 August 2017

Abstract

Background

Ataxia telangiectasia (A-T) is a neurodegenerative disease that leads to mitochondrial dysfunction and oxidative stress. Insulin resistance (IR), type 2 diabetes and the risk for development of cardiovascular disease was recently associated as an extended phenotype of the disease. We aimed to assess IR; liver involvement; carotid intima-media thickness (cIMT) and metabolic alterations associated to cardiovascular risk in A-T patients, and relate them with age.

Results

Glucose metabolism alterations were found in 54.6% of the patients. Hepatic steatosis was diagnosed in 11/17 (64.7%) A-T patients. AST/ALT ratio > 1 was observed in 10/17 (58.8%). A strong positive correlation was observed between insulin sum concentrations with ALT (r = 0.782, p < 0.004) and age (r = 0.818, p = 0.002). Dyslipidemia was observed in 55.5% of the patients. The apolipoprotein (Apo-B)/ApoA-I ratio (r = 0.619; p < 0.01), LDL/HDL-c (r = 0.490; p < 0.05) and the Apo-B levels (r = 0.545; p < 0.05) were positively correlated to cIMT.

Conclusions

Metabolic disorders implicated in cardiovascular and liver diseases are frequently observed in adolescent A-T patients and those tend to get worse as they become older. Therefore, nutritional intervention and the use of drugs may be necessary.

Keywords

Ataxia Telangiectasia Atherosclerosis Carotid Intima-media thickness Insulin resistance Fatty liver disease Dyslipidemia Nutritional status Diabetes

Background

Clinical and biochemical alterations, such as reduction of lean mass, premature aging, insulin resistance (IR), type 2 diabetes, and risk of developing cardiovascular (CV) disease [1] have been recently added to the classic phenotype of ataxia telangiectasia (A-T).

The disease is caused by mutations in the ataxia-telangiectasia mutated (ATM) gene [2] and causes reduction in antioxidant cell capacity and constant oxidative stress that are related to the development of chronic morbidities [3, 4].

ATM-deficient mice showed glucose intolerance, IR, and impaired insulin secretion whose mechanisms are not fully known [5, 6]. A recent study showed high blood glucose and low insulin sensitivity in patients with A-T compared to healthy controls [7].

Literature is still scarce regarding the liver changes observed in A-T patients. A mouse model study emphasized the important role of the ATM pathway in liver fat accumulation and has associated its activation to steatohepatitis-apoptosis and fibrosis – both considered important findings for the progression of nonalcoholic fatty liver disease (NAFLD) [8].

Regarding the CV risk, an ATM study with apolipoprotein (Apo) E-deficient mice has described the emergence of atherosclerotic lesions with accelerated progression in association with IR and glucose intolerance [9]. Furthermore, it was found that ATM deficiency resulted in an increased c-jun N terminal kinase (JNK) activity related to metabolic syndrome [10], failure in the regulation of the Nuclear Factor kappa B (NF-kB) expression, increased production of free radicals, and reduction of oxidative phosphorylation, leading to changes in lipid and glucose metabolism [11].

The CV risk can be assessed by biochemical methods and non-invasive imaging techniques, such as carotid intima-media thickness (cIMT) by ultrasonography (US). A previous study conducted by our group has identified significant changes in triglyceride levels (TG), cholesterol fractions of Non-HDL-c (NHDL-c), and in the relationship between CT/HDL-c and LDL-c/HDL-c in patients with A-T [12].

Given the lack of studies on the metabolic changes observed in A-T involved in the risk of developing chronic diseases, the aim of this study was to assess IR; liver involvement; carotid intima-media thickness (cIMT) and metabolic alterations associated to cardiovascular risk in A-T patients, and relate them with age.

Methods

In a cross-sectional controlled study, we evaluated 18 A-T patients of both genders, between 5 and 25 years of age, who were diagnosed with A-T according to the criteria of the European Society for Immunodeficiencies (ESID) [13]. The control group was composed by 17 healthy individuals matched in age, gender and pubertal stage; it was used to compare biochemical markers related to cardiovascular risk and food intake. The study was approved by the Research Ethics Committee from the Federal University of São Paulo (UNIFESP). Patients and controls with acute infection at the time of collection were exclude, as well as those using oral corticosteroids or hypoglycemic agents in the 3 months prior to collection.

Anthropometric evaluation and food intake

The anthropometric evaluation included the measurement of weight, height, mid-upper arm circumference (MUAC) and skinfold thickness (tricipital, subscapular, bicipital, and sacroiliac). The patients who were unable to stand upright were weighed in their parent’s arms and their recumbent height was measured on a firm, flat surface using an inextensible tape that was graduated in millimeters.

In order to classify nutritional status, body mass index to age z-score (ZBMI) for children/adolescents and body mass index (BMI) for adults were calculated. The sum of skinfold thickness and MUAC was used to estimate body composition [1417]. Pubertal stage was evaluated according to Marshall and Tanner [18].

The assessment of food intake was performed using a 24 h dietary recall (R24hs). The calculation of nutrients in the diet was performed by use of the software Diet Win® and was analyzed according to Dietary Reference Intakes (DRIs) [19]. None of A-T patients had feeding tubes.

CV risk assessment

The lipid profile [triglycerides (TG), total cholesterol (TC), HDL-c, and LDL-c] was measured with enzymatic-colorimetric tests [20, 21]. The non-HDL cholesterol (NHDL-c) values were obtained by subtracting the HDL-c values from the TC values [21, 22]. Apo A-I, Apo B, small-dense LDL-c particles (sdLDL), oxidized LDL (LDL-ox) and lipoprotein (a) [Lp(a)] were assessed by immune turbid metric assays (ELISAPRO® Human Mabitech Kit).

The assessment of the carotid intima media thickness (cIMT) was performed only in A-T patients in a blinded fashion by a single examiner who used Doppler Ultrasonography (Medison equipment, Accuvix V10 model with linear transducer of high frequency of 6 - 12 MHz). A short length no longer than 0,5 cm of the distal common carotid artery was chosen, at a distance of 1 cm from the bulb, in which three equidistant measurements of cIMT were taken from the far wall and mean values were considered [23].

Liver involvement

The biochemical markers were collected for hepatic evaluation such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). AST/ALT ratio > 1 was considered as indicative of liver fibrosis. Hepatic steatosis was evaluated by ultrasonography in a blinded fashion by a single examiner [24]. Liver involvement was considered when the A-T patients presented hepatic steatosis plus ALT higher than 40 U/L (reference value) or only ALT higher than 40 U/L.

Assessment of IR

Standard 75-g oral glucose tolerance test (OGTT): glucose and insulin levels were measured at 0, 30, 60, 90, and 120 min. Glucose intolerance was considered when, at 120 min, glycaemia was ≥140 mg/dL and <200 mg/dL and IR was considered when the sum of the five insulin levels measured were >300mUI/mL [25].

Statistical analysis

The statistical package SPSS 24.0 was used for the analysis. Continuous variables were tested for normality. For comparisons between nonparametric variables, the Mann-Whitney or Kruskal-Wallis test was used and, for the parametric variables, the t-Student or ANOVA test was used. The Chi-square test or Fisher’s exact test was used to analyze the association between qualitative variables. We used Pearson’s and Spearman’s correlation coefficient for comparing the analyzed parameters. A significance level of 5% (p < 0.05) was adopted.

Results

The mean age of A-T patients was 13.9 years old, with 15 (83.3%) males and 9 (50%) pre-pubertal. Eleven out of 18 (61.1%) received regular immunoglobulin infusion. The classification of nutritional status by BMI and MUAC are in Table 1 and more than 50% of the patients had dyslipidemia. Glucose metabolism alterations were found in 6/11 (54.6%) patients. One patient was diagnosed with diabetes mellitus (Table 1).
Table 1

Characterization of patients with A-T

Variable

 

N (%)

Age (n = 18)

5–15 years

12 (66.6%)

16–25 years

6 (33.3%)

Nutritional status (n = 18)

Malnutrition

6 (33.3%)

Normal body mass index

11 (61.1%)

Overweight

1 (5.5%)

Fat mass (n = 18)

Low

2 (11.1%)

Adequate

9 (50.0%)

High

7 (38.9%)

Mid-upper arm muscle circumference (n = 18)

Low

10 (55.5%)

Adequate

8 (44.4%)

Lipid profile (n = 18)

High total cholesterol

10 (55.5%)

High LDL-c

10 (55.5%)

High triglyceride

8 (44.4%)

Low HDL-c

10 (55.5%)

High NHDL-c

11 (61.1%)

Diabetes mellitus (n = 18)

>200 mg/dL

1 (5.5%)

Oral Glucose Tolerance Test (n = 11)

Normal

5 (45.4%)

Glucose intolerance

1 (9.1%)

Insulin resistance

4 (36.4%)

Glucose intolerance and Insulin resistance

1 (9.1%)

ALT (n = 17)

> 40 U/L

7 (41.2%)

AST/ALT (n = 17)

> 1

10 (58.8%)

Hepatic steatosis (n = 17)

No

6 (35.3%)

Mild

7 (41.2%)

Moderate

4 (23.5%)

Liver involvement (n = 17)

 

7 (41.2%)

N (%)

Legend: LDL-c low density lipoprotein cholesterol, HDL-c high density lipoprotein cholesterol, NHDL-c Non-HDL-c, ALT alanine aminotransferase, and AST/ALT aspartate aminotransferase/alanine aminotransferase

Hepatic steatosis was diagnosed in 11/17 (64.7%) A-T patients. AST/ALT ratio > 1 was observed in 10/17 (58.8%) (Table 1). The mean ALT and AST levels, and AST/ALT ratio was 37.7 ± 27.1 U/L, 34.3 ± 11.6 U/L e 1.3 ± 0.7 U/L, respectively. It is also important to note those patients with elevated ALT levels, these levels remained elevated at 6-months clinical follow up (data not shown). Table 2 shows individual ALT and AST values for A-T patients.
Table 2

Alanine aminotransferase and aspartate aminotransferase values of the A-T group

A-T Group (n = 17)

Aspartate aminotransferase (U/L)

Alanine aminotransferase (U/L)

1

25

10

2

21

14

3

35

28.1

4

51

99.8

5

27

12.2

6

24

23.5

7

34

22.3

8

34

18.6

9

66

49

10

19

50

11

27

17

12

36

13

13

30

59

14

41

50

15

40

90.8

16

31

31.8

17

43

52.7

Malnutrition and overweight were observed in 6/18 (33.3%) and 1/18 (5.5%) A-T patients, respectively. In the control group, malnutrition and overweight were verified in 1/17 (5.9%) and 7/17 (41.2%), respectively. Despite the fact, that the mean BMI (17.3 ± 4.0 kg/m2 vs 21.3 ± 4.8 kg/m2; p = 0.010) was lower in A-T patients we observed in this group in comparison to controls higher levels of Apo B (274.1 ± 184.4 mg/mL vs 167.0 ± 46.0 mg/mL; p = 0.027); ApoB/Apo A1 ratio (2.1 ± 1.4 vs 1.2 ± 0.3; p = 0.018) and Lp(a) (182.8 (31.2;585.8) pg/mL vs 31.2 (31.2;334.9) pg/mL; p < 0.001) suggestive ofa more atherogenic lipid profile (Table 3).
Table 3

Comparison of the variables in A-T group and control group

Variable

 

A-T Group (n = 18)

Controls (n = 17)

p Value

Total cholesterol

mg/dL

177.4 ± 33.3

170.0 ± 25.4

0.448a

LDL-c

mg/dL

115.4 ± 32.3

107.6 ± 22.3

0.412a

HDL-c

mg/dL

43.5 ± 10.8

45.2 ± 8.1

0.596a

Triglycerides

mg/dL

94.1 ± 47.2

91.7 ± 45.8

0.880a

Non-HDL-cholesterol

mg/dL

134.2 ± 35.7

124.8 ± 25.6

0.377a

Total cholesterol/HDL-c

mg/dL

4.3 ± 1.4

3.9 ± 0.9

0.265a

LDL/HDL

mg/dL

2.8 ± 1.1

2.5 ± 0.8

0.272a

Apo A-I

mg/mL

130.8 ± 27.2

138.8 ± 19.8

0.330a

Apo B

mg/mL

274.1 ± 184.4

167.0 ± 46.0

0.027 a

Apo B/Apo AI

mg/mL

2.1 ± 1.4

1.2 ± 0.3

0.018 a

LDL/ApoB

mg/mL

0.56 ± 0.42

0.67 ± 0.15

0.327a

Lp(a)

pg/mL

182.8 (31.2;585.8)

31.2 (31.2;334.9)

0.001 b

LDLox

pg/mL

2610.0 ± 985.0

2338.4 ± 982.6

0.533a

sdLDL-c

mmol/L

3.3 ± 0.9

3.2 ± 0.9

0.641a

aSignificance level of the t-Student test.b Significance level of the Mann-Whitney test

Legend: LDL-c low density lipoprotein cholesterol, HDL-c high density lipoprotein cholesterol, TC total cholesterol, Apo AI apolipoprotein A, Apo B apolipoprotein B, LDLox oxidized LDL and Lp(a) [lipoprotein (a)]

The bold text means the p-value of satistical tests (t-Student1 or Mann-Witney2 are less than p< 0,05 (there was statistical significance)

The mean cIMT of A-T patients was 0.42 mm (range: 0.20 and 0.50). The ApoB/ApoA-I ratio (r = 0.619; p < 0.01), LDL/HDL-c (r = 0.490; p < 0.05), and the ApoB values (r = 0.545; p < 0.05) were positively correlated to cIMT.

Figure 1 shows the correlation between insulin sum concentrations of the OGTT, in A-T patients, with ALT (r = 0.782, p < 0.004) and age (r = 0.818, p = 0.002). We observed a strong positive correlation between insulin sum concentrations with ALT and age. The strongest was with age.
Fig. 1

Correlation between insulin sum concentrations of the oral glucose tolerance test (n = 11) in patients with A-T with ALT (n = 17) and age (n = 18). *Significance level of Spearman correlation test

Figure 2 shows that patients who presented with liver involvement had higher sum of insulin levels [590.7 μU/mL (19.1;153.3); p = 0.047] and older age (20.2 ± 4.5 years of age; p = 0.001) as compared to those patients who had only hepatic steatosis [86.2 μU/mL (19.1;152.3) /10 ± 5.2 years of age] and those without liver involvement [148.1μU/mL (63.1;415.9) /9.9 ± 2.1 years of age].
Fig. 2

Insulin sum concentrations of the oral glucose tolerance test in A-T patients (n = 11) without liver involvement, with hepatic steatosis only and with liver involvement; association with age. * Significance level of the test: ANOVA for patients without liver involvement, only hepatic steatosis and with liver involvement vs age (years), * p = 0.001. Kruskal-Wallis test for patients without liver involvement, only hepatic steatosis and with liver involvement vs insulin sum concentrations (μU/mL), * p = 0.047

There were no differences regarding energy and macronutrients intake between A-T group and control group (Table 4).
Table 4

Comparison of the means of energy and macronutrients intake in A-T group and control group

Variable

 

A-T Group (n = 18)

Controls (n = 17)

p Value

Energy

Kcal

1718.4 ± 777.9

1709.5 ± 505.0

0.970a

Protein

grams

79.8 ± 35.9

74.4 ± 25.8

0.634a

Carbohydrate

grams

237.2 ± 116.5

224.7 ± 81.2

0.729a

Total fat

grams

51.2 ± 27.0

57.6 ± 18.4

0.447a

Saturated fat

grams

19.6 ± 11.0

21.1 ± 7.8

0.659a

Cholesterol

mg

205.9 ± 152.1

189.5 ± 118.7

0.737a

aSignificance level of the t-Student test

Discussion

This study emphasizes the CV, diabetes, and liver disease risks in A-T patients evidenced by atherogenic lipid profile [higher values of Lp(a) and ApoB/Apo A-I], IR, and presence of hepatic steatosis in 64.7% of the patients. Moreover, it was found that the increase in age was a risk factor for insulin resistance and liver involvement.

The ATM activity seems to be implicated in the glycemic response to metformin in type 2 diabetes [26] and in CV disease [27].

Over time, patients with A-T develop a catabolic condition associated with decline in BMI, chronic lung disease, worsening of hepatic function and glucose metabolism [28], as observed in our study. A recent retrospective cohort study of 55 patients with A-T found endocrine abnormalities, such as diabetes, dyslipidemia, and changes in liver function in two adults [29].

It is known that IR and atherosclerosis are risk factors for developing CV disease, with oxidative stress being related to both complications [30, 31]. IR is also implicated as a key factor in the pathogenesis of steatohepatitis [32], with a positive association of oxidative stress and the severity of liver disease in humans [33]. The deficiency of ATM protein is presented as an important link between the metabolic changes observed in A-T patients.

A recent study, such as observed by us, has found higher glycemia and lower insulin sensitivity in patients with A-T [9]. Some hypotheses can be raised to explain this finding, such as the participation of the ATM in the insulin signaling pathway via phosphorylation of eIF-4E (eukaryotic translation initiation factor 4E) [34] and the regulation exerted by the serine-threonine kinase protein (AKt) or protein kinase B (PKB) activity, which regulates glucose-transporter 4 (GLUT4) translocation by insulin in skeletal muscle and adipose tissue [35].

In our study, abnormalities in glucose metabolism were observed in all pubertal patients who underwent the test. This finding strongly recommends the importance of performing the OGTT in all A-T pubertal patients aimed an early detection of glucose metabolism disorders.

Inflammation is an important factor for the development of obesity-induced IR and it involves tissue immune cells, including phagocytes, lymphocytes, and cytokines [36]. Only one of our patients was obese, showing that this condition is not the cause of IR. Recently, it was demonstrated that the neutrophils from A-T patients produce significantly more cytokines and live longer compared to those from controls, suggesting that innate immune dysfunction may drive inflammation in A-T patients [37]. In a cross-sectional study, the geometric mean of interleukin (IL)-8 level was significantly higher in A-T patients compared with non-A-T (p < .0001) [38]. McGrath-Morrow et al. [39] found that approximately 80% of the A-T patients had elevated levels of serumIL-6 and 23.6% having increased levels of IL-6 and IL-8. Furthermore, serum IL-6 levels were correlated with lower lung function.

There are evidences that apolipoproteins are better predictors of CV risk compared to the classic lipid profile [40] and, the Apo B/Apo A-I ratio seems to be a better CV risk predictor [41] that was abnormal in our patients in addiction to the cIMT alteration.

One third of our A-T patients presented undernutrition and 55.5% of them had a compromised body mass. Only 11.1% of the patients had deficit of body fat, which indicates that malnutrition in these patients is associated with reduced lean mass. It is also important to note that of the six patients with glucose metabolism disorders and one with diabetes, five of them had compromised lean mass and six had high NHDL-c values, which reinforces risk factors for developing CV disease dependent on ATM activity (data not shown).

A retrospective cohort study of 53 patients with A-T found liver enzyme abnormalities in 43.4% (23/53) and the presence of steatosis by US in 39% (9/23). Liver biopsy was performed in two patients and showed mild to moderate steatosis in both of them and fibrosis in one of them, supporting our results [42]. Recently, nonalcoholic steatohepatitis without ATM protein in the nucleus of the hepatocytes was showed in a liver biopsy in one A-T patient [43]. One of our patients not included in this study, passed away at 30 years of age with liver cirrhosis, suggesting that this morbidity could affect older A-T patients. The small sample size of this study is a limitation, but for the first time in the literature, we described the association between IR and liver involvement which leads us to recommend the evaluation of glucose metabolism, liver function and US in A-T adolescents. Further studies are necessary to clarify the role of ATM protein in those mechanisms.

Conclusions

Metabolic disorders implicated in cardiovascular and liver involvement are observed in adolescent A-T patients and those tend to get worse as they become older. Drugs usually employed in diabetes, dyslipidemia and metabolic syndrome have unconvincing results in A-T patients, stressing the need for new treatment alternatives. Therefore nutritional intervention encouraging the use of antioxidants nutrients and new drugs, taking account the pathophysiology of the disease and side effects may be necessary.

Abbreviations

ALT: 

Alanine aminotransferase values

ATM: 

Ataxia telangiectasia mutated

BMI: 

Body mass index

CIMT: 

Carotid intima-media thickness

CVD: 

Cardiovascular disease

DRI: 

Dietary Reference Intakes

IR: 

Insulin resistance

JNK: 

Jun N terminal kinase

MUAC: 

Mid-upper arm circumference

MUAMC: 

Mid-upper arm muscle circumference

OGTT: 

Oral glucose tolerance test

TC: 

Total cholesterol

TG: 

Triglyceride levels

US: 

Ultrassonography

ZBMI: 

Body mass index to age z-score

Declarations

Acknowledgements

We thank the team and Professors Dr. Vania D’Almeida and Dr. Fernando Luiz Affonso Fonseca for the Laboratory of Inborn Errors of Metabolism of the UNIFESP/EPM and Clinical Analyses Laboratory of the Faculdade de Medicina do ABC. We also thank patients, parents and volunteers and the A-T/Brazil project, all of whom made this study possible.

Funding

This work also was supported in part by CAPES Foundation, Ministry of Education of Brazil, Brasilia DF 70040-020, Brazil.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Authors’ contributions

TLP and MNR contributed equally to the authorship, carried out the acquisition of data and drafting of the manuscript, and provided final approval of the version to be published. SH carried out the analysis and interpretation of data. DCS and SAA carried out the analysis and interpretation of data. FISS carried out the statistical analysis and interpretation of data of the manuscript. CK carried out the analysis, the interpretation data and a critical revision for important intellectual content. RS carried out the analysis, the interpretation data and a critical revision for important intellectual content. BTCC conceived the study, participated in design development and drafting of the manuscript; carried out study supervision, critical revision for important intellectual content and provided final approval of the version to be published. ROSS conceived of the study, and participated in design development and drafting of the manuscript; carried out study supervision and critical revision for important intellectual content and provided final approval of the version to be published. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Research Ethics Committee from the Federal University of São Paulo (UNIFESP), identification numbers 041733/2013 and 347,654/2013.

Consent for publication

Patients and parents gave consent to be included in the study through consent form.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Pediatrics, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP)
(2)
Department of Morphology and Physiology, Faculdade de Medicina do ABC, ABC Foundation (FMABC)
(3)
Department of Diagnostic Imaging, Escola Paulista de Medicina, Federal University of São Paulo (UNIFESP)
(4)
Santa Casa de Sao Paulo School of Medical Sciences (FCMSCSP)
(5)
School of Nutrition, Federal University of Alfenas (UNIFAL

References

  1. Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood. 2013;121:4036–45.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Patanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NG, Taylor AM, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268:1749–53.View ArticlePubMedGoogle Scholar
  3. Semlitsch M, Shackelford RE, Zirkl S, Sattler W, Malle E. ATM protects against oxidative stress induced by oxidized low-density lipoprotein. DNA Repair. 2011;10:848–60.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Reinbach J, Schubert R, Schindler D, Muller K, Bohles H, Zielen S. Elevated oxidative stress in patients with ataxia telangiectasia. Antiox Redox Signal. 2002;4:465–9.View ArticleGoogle Scholar
  5. Bar RS, Levis WR, Rechler MM, Harrison LC, Siebert C, Podskalny J, Roth J, Muggeo M. Extreme insulin resistance in ataxia telangiectasia: defect in affinity of insulin receptors. N Engl J Med. 1978;298:1164–71.View ArticlePubMedGoogle Scholar
  6. Schalch DS, McFarlin DE, Barlow MH. An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med. 1970;282:1396–402.View ArticlePubMedGoogle Scholar
  7. Connelly PJ, Smith N, Chadwick R, Exley AR, Shneerson JM, Pearson ER. Recessive mutations in the cancer gene ataxia Telangiectasia mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance. Diabet Med. 2016;33:371–5.View ArticlePubMedGoogle Scholar
  8. Daugherity EK, Balmus G, Al Saei A, Moore ES, AbiAbdallah D, Rogers AB, Weiss RS, Maurer KJ. The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease. Cell Cycle. 2012;11:1918–28.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Wu D, Yang H, Xiang W, Zhou L, Shi M, Julies G, Laplante JM, Ballard BR, Guo Z. Heterozygous mutation of ataxia-telangiectasia mutated gene aggravates hypercholesterolemia in apoE-deficient mice. J Lipid Res. 2005;46:1380–7.View ArticlePubMedGoogle Scholar
  10. Schneider JG, Finck BN, Ren J, Standley KN, Takagi M, Maclean KH, Bernal-Mizrachi C, Muslin AJ, Kastan MB, Semenkovich CF. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab. 2006;4:377–89.View ArticlePubMedGoogle Scholar
  11. Mercer JR, Cheng KK, Figg N, Gorenne I, Mahmoudi M, Griffin J, Vidal-Puig A, Logan A, Murphy MP, Bennett M. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ Res. 2010;107:1021–31.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Andrade IG, Costa-Carvalho BT, da Silva R, Hix S, Kochi C, Suano-Souza FI, Sarni RO. Risk of atherosclerosis in patients with ataxia Telangiectasia. Ann Nutr Metab. 2015;66:196–201.View ArticlePubMedGoogle Scholar
  13. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (pan-American Group for Immunodefiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999;93:190–7.View ArticlePubMedGoogle Scholar
  14. Lohman TG. Advances in body composition assessment: current issues in exercises science. Illinois: Human Kinetic Publisher; 1992. p. 335.Google Scholar
  15. Slaughter MH, Lohman TG, Boileau RA, Horswill CA, Stillman RJ, Van Loan MD, Bemben DA. Skinfold equations for estimation of body fatness in children and youth. Hum Biol. 1988;60:709–23.PubMedGoogle Scholar
  16. Deurenberg P, Pieters JJ, Hautuast JG. The assessment of the body fat percentage by skinfold thickness measurement in childhood e young adolescent. Br J Nutr. 1990;63:293–303.View ArticlePubMedGoogle Scholar
  17. Blackburn GL, Thornton PA. Nutritional assessment of the hospitalized patients. Med Clin North Am. 1979;63:11103–15.View ArticlePubMedGoogle Scholar
  18. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls and boys. Arch Dis Child. 1969;44:291–303.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Trumbo P, Schlicker S, Yates AA, Poos M, Food and Nutrition Board of the Institute of Medicine, The National Academies. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 2002;102:1621–30.View ArticlePubMedGoogle Scholar
  20. Daniels SR. Greer FR; committee on nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122:198–208.View ArticlePubMedGoogle Scholar
  21. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–421.Google Scholar
  22. Srinivasan SR, Frontini MG, Xu J, Berenson GS. Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa heart study. Pediatrics. 2006;118:201–6.View ArticlePubMedGoogle Scholar
  23. Sarmento PL, Plavnik FL, Zanella MT, Pinto PE, Miranda RB, Ajzen SA. Association of carotid intima-media thickness and cardiovascular risk factors in women pre- and post-bariatric surgery. Obes Surg. 2009 Mar;19(3):339–44.View ArticlePubMedGoogle Scholar
  24. Scatarige JC, Scott WW, Donovan PJ, Siegelman SS, Sanders RC. Fatty infiltration of the liver: ultrasonographic and computed tomographic correlation. J Ultrasound Med. 1984;3:9–14.View ArticlePubMedGoogle Scholar
  25. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183–97.View ArticleGoogle Scholar
  26. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2, Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ, Burch L, Carr F, Strange A, Freeman C, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Gray E, Hunt S, Jankowski J, Langford C, Markus HS, Mathew CG, Plomin R, Rautanen A, Sawcer SJ, Samani NJ, Trembath R, Viswanathan AC, Wood NW, MAGIC investigators, Harries LW, Hattersley AT, Doney AS, Colhoun H, Morris AD, Sutherland C, Hardie DG, Peltonen L, MI MC, Holman RR, Palmer CN, Donnelly P, Pearson ER. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2011;43:117–20.View ArticleGoogle Scholar
  27. Bobak I, Kleber ME, Maerz W, Rudofsky G, Dugi KA, Schneider JG. Association between a gene variant near ataxia telangiectasia mutated and coronary artery disease in men. Diab Vasc Dis Res. 2014;11:60–3.View ArticlePubMedGoogle Scholar
  28. Voss S, Pietzner J, Hoche F, Taylor AM, Last JI, Schubert R, Zielen S. Growth retardation and growth hormone deficiency in patients with ataxia telangiectasia. Growth Factors. 2014;32:123–9.View ArticlePubMedGoogle Scholar
  29. Nissenkorn A, Levy-Shraga Y, Banet-Levi Y, Lahad A, Sarouk I, Modan-Moses D. Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort. Pediatr Res. 2016;79:889–94.View ArticlePubMedGoogle Scholar
  30. Bloch-Damti A, Bashan N. Proposed mechanisms for the induction of insulin resistance by oxidative stress. Antioxid Redox Signal. 2005;7:1553–67.View ArticlePubMedGoogle Scholar
  31. Evans JL, Maddux BA, Goldfin ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal. 2005;7:1040–52.View ArticlePubMedGoogle Scholar
  32. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48:634–42.View ArticlePubMedGoogle Scholar
  33. Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2010;38:2293–30.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Yang DQ, Kastan MB. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol. 2000;2:893–8.View ArticlePubMedGoogle Scholar
  35. Halaby MJ, Hibma JC, He J, Yang DQ. ATM protein kinase mediates full activation of Akt and regulates glucose transporter 4 translocation by insulin in muscle cells. Cell Signal. 2008;20:1555–63.View ArticlePubMedGoogle Scholar
  36. Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta. 1842;2014:446–62.Google Scholar
  37. Harbort CJ, Soeiro-Pereira PV, Von Bernuth H, Kaindl AM, Costa-Carvalho BT, Condino-Neto A, Reichenbach J, Roesler J, Zychlinsky A, Amulic B. Neutrophil oxidative burst activates ATM to regulate cytokine production and apoptosis. Blood. 2015;126:2842–51.View ArticlePubMedPubMed CentralGoogle Scholar
  38. McGrath-Morrow SA, Collaco JM, Crawford TO, Carson KA, Lefton-Greif MA, Zeitlin P, Lederman HM. Elevated serum IL-8 levels in ataxia telangiectasia. J Pediatr. 2010;156(4):682–4. e681View ArticlePubMedGoogle Scholar
  39. McGrath-Morrow SA, Collaco JM, Detrick B, Lederman HM. Serum interleukin-6 levels and pulmonary function in ataxia-Telangiectasia. J Pediatr. 2016;171:256–61. e251View ArticlePubMedGoogle Scholar
  40. Simon A, Chironi G, Levenson J. Comparative performance of subclinical atherosclerosis tests in predicting coronary heart disease in asymptomatic individuals. Eur Heart J. 2007;28:2967–71.View ArticlePubMedGoogle Scholar
  41. Srinivasan SR, Berenson GS. Serum apolipoproteins AI and B as markers of coronary artery disease risk in early life: the Bogalusa heart study. Clin Chem. 1995;41:159–64.PubMedGoogle Scholar
  42. Weiss B, Krauthammer A, Soudack M, Lahad A, Sarouk I, Somech R, Heimer G, Ben-Zeev B, Nissenkorn A. Liver disease in pediatric patients with ataxia Telangiectasia: a novel report. J Pediatr Gastroenterol Nutr. 2016;62:550–5.View ArticlePubMedGoogle Scholar
  43. Caballero T, Caba-Molina M, Salmerón J, Gómez-Morales M. Nonalcoholic steatohepatitis in a patient with ataxia-telangiectasia. Case Reports Hepatol. 2014;2014:761250.PubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement